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Abstract
Neurotic disorders (NDs) are among the most common mental diseases leading
to a decrease in the quality of life, lack of socialization, and increased mortality. The
diagnosis and treatment of all types of NDs are challenging. In the light of the
ongoing search for an effective and safe therapeutic strategy influencing certain
aspects of ND pathogenesis, technologically processed highly diluted antibodies to
S100 protein (TP Abs to S100) seem to be a promising treatment option for patients
with NDs. TP Abs to S100 possess stress-protective, anxiolytic, antidepressant,
antiamnestic, and neuroprotective activities. In the current review, we describe the
mechanisms of action and pharmacological effects of TP Abs to S100 demonstrated
in nonclinical (preclinical) and clinical studies. Based on the data, we tried to
evaluate the future prospects of the TP Abs to S100 as the drug of choice for ND
treatment.
Keywords: neurotic disorder, anxiety, anxiolytic therapy, S100 protein,
somatoform disorder
1. Introduction
Neurotic disorders (NDs) are among the most common mental diseases leading
to a decrease in the quality of life, lack of socialization, and increased mortality [1].
Around 20–40% of primary care outpatients are diagnosed with NDs according to
International Disease Classification (ICD)-10 or Diagnostic and Statistical Manual
of Mental Disorders (DSM) V criteria [2].
ICD-10 classification of the NDs F40–F48 includes phobic anxiety disorders
(F40), other anxiety disorders (AD, F41), obsessive-compulsive disorder (OCD,
F42), reaction to severe stress, adjustment disorders (F43), dissociative and con-
version disorders (F44), somatoform disorders (SD, F45), and other nonpsychotic
mental disorders (F48). In the DSM V, the same disorders are classified as Anxiety
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Disorders, Obsessive-Compulsive and Related Disorders, Trauma- and Stressor-
Related Disorders, Dissociative Disorders, and Somatic Symptom Disorder [3, 4].
Phobias are present in 1.3–5.7% of all NDs [5]. Anxiety symptoms are thought to
occur in every 14th person during the lifetime [6]. The prevalence of SD is 20–25%,
but at least one medically unexplained symptom is found in 40–49% of patients
[7, 8]. Around 10% of all psychiatric patients have dissociative disorder [9, 10].
A lifetime prevalence of OCD is 2.3%, and the rate of adjustment disorder is
1–2% [5].
The overlaps between AD, phobias, and SD were shown and considered a result
of similarity of pathogenesis, which involves disturbances in hypothalamic-
pituitary-adrenal axis (HPAA), cytokine levels, and changes in the state of recep-
tors in the nervous system [11–15]. Continued and prolonged stress may disturb the
HPAA to such an extent that the negative feedback mechanisms (glucocorticoid
negative feedback, in particular) are disrupted, and the adaptive responses of the
HPAA may then become maladaptive. Enhanced proinflammatory cytokine pro-
duction and overactivation of the sympathetic nervous system contribute to a state
of chronic low-grade inflammation.
NDs have a great social impact. A British survey (1993) reported that 8.3% of
10,000 responders had ND limiting their daily activities and 3.4% experienced
severe “disabling” NDs, associated with a higher chance of being unemployed [16].
The cost of AD treatment in the European Union was approximately 41 billion € in
2004 and 66 billion € in 2010 [17, 18]. Taking into consideration the prediction of
the growing influence of mental health problems on the economic output by 2030
[19], we expect the increasing burden of NDs.
The diagnosis and treatment of all types of NDs are challenging. More than 20%
of AD patients are undertreated and continue to suffer from symptoms [11]. A
study by Wang revealed a 2–3-year delay in the diagnosis of NDs [20]. Around 40–
66% of SD cases are underdiagnosed in primary care [21]. The first line of treatment
for most of NDs is selective serotonin reuptake inhibitors (SSRIs). Nevertheless,
their efficacy and safety are still under consideration. The high placebo effect was
shown in randomized controlled studies of SSRI in the treatment of phobic disorder,
OCD, and generalized anxiety disorder (GAD) [22]. There are only 40–60% of
responders to first-line therapy among OCD patients [23]. In the Cochrane review
by Kleinstaeuber et al., low-quality evidence for the efficacy of new generation
antidepressants in SD was obtained [24]. Adverse events such as insomnia, nausea,
sexual dysfunction, and withdrawal are common for SSRI. Negative drug interac-
tions are also limiting their use in patients receiving therapy for somatic diseases.
Other antidepressant drugs such as tricyclic antidepressants (TCA) have been
shown to be effective for the treatment of some NDs in several trials, although the
Cochrane review did not reveal any significant differences in the comparison of
tricyclic antidepressants (TCA) and other medications in SD [24]. The safety profile
of TCA is more unfavorable than SSRI. The use of benzodiazepines in ADs is limited
due to the sedation, myorelaxant effect, and negative impact on cognition they
provoke in long-term use. Among nonpharmacological treatments, only cognitive
behavioral therapy was shown to be effective with greater results in combination
with medication [22].
In the light of the ongoing search for an effective and safe therapeutic strategy
influencing certain aspects of ND pathogenesis, technologically processed highly
diluted antibodies to the brain specific S100 protein (TP Abs to S100) seem to be a
perspective substance for treatment.
In the central nervous system (CNS), the brain-specific S100 protein is
synthesized mainly by astrocytes and then transported to neurons where it is
involved in numerous processes. In particular, it was shown that S100 affects the
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differentiation and survival of neurons, the growth of dendrites, the integrity of
cytoskeleton, and energy metabolism [25].
Increased level of S100 is considered a marker of blood brain barrier failure.
S100 serum levels are elevated after stroke, subarachnoid hemorrhage, and brain
trauma and correlate positively with patient outcome. However, the brain-specific
S100 protein may be secreted peripherally, and its elevated serum levels are also
found in heart diseases and infections. High serum levels of the brain-specific S100
protein are also found in patients with schizophrenia, depressive/bipolar disorders,
and obesity, but which cells are the sources of S-100 protein in these conditions is
unknown [25, 26].
A number of nonclinical studies of TP Abs to S100 efficacy, safety, and mecha-
nisms of action using the commonly applied experimental in vivo and in vitro
models preceded clinical investigation. While studying the drug’s primary and
secondary pharmacodynamics, it was shown that TP Abs to S100 exert stress-
protective [27], anxiolytic [28–33], antidepressant [30, 31, 34], antiamnestic
[35–37], and neuroprotective [38, 39] activities.
Target identification and mechanism-of-action studies revealed that the drug
recruits serotonin-, dopamine-, GABA-, noradrenaline-, and glutamatergic systems
[29, 30, 40–42] and thereby might be considered a player in various
neurotransmitter-mediated processes. Moreover, TP Abs to S100 influence sigma1
receptor [41] that in turn modulates the activity of almost all neurotransmitter
systems and thereby possesses a spectrum of psychotropic activities [43, 44].
Data on the TP Abs to 100 mechanisms of action and identified pharmacody-
namics of the drug are consistent with the literature data on the relationship
between influencing certain neurotransmitter systems (their receptors) and
observing subsequent psychotropic effects. For example, it is known that benzodi-
azepines mediate their anxiolytic activity and sedation via GABAA receptors
[45, 46]. GABAB receptor agonists are known to attenuate the behavioral deficit-
restoring effect of antidepressants [47, 48]. Ligands of 5-HT1A, 5-HT1B, 5-HT1F,
5-HT2а, 5-HT2B, 5-HT2C, and 5-HT3 receptors were shown to regulate aggression,
anxiety, learning, addiction, locomotion, memory, mood, and so on [49]. Ligands of
the glycine site of the NMDA receptor exhibit anxiolytic and antidepressant prop-
erties and impact memory-related processes [50–53, 80]. D3 receptor deficiency can
result in chronic depression and anxiety [54]. Sigma1 receptor ligands have a whole
spectrum of psychotropic effects due to their modulating effect on all major neuro-
transmitter systems [43, 44], which also are in line with TP Abs to S100 mechanism
of action.
More than 2000 patients with GAD (F41.1), SD (F45), adjustment disorders
(AjDs) (F43.2), neurasthenia (F48.0), and anxiety accompanying somatic diseases
(cardiovascular and gastrointestinal disorders) took part in phase III, IV, and post-
marketing clinical trials (CTs) of TP Abs to S100, including two double-blind
placebo-controlled randomized CTs and nine open-label comparative randomized
CTs [55–57]. TP Abs to S100 were shown to be as effective as clonazepam 0.5–1
mg/day, bromdihydrochlorphenylbenzodiazepine 1.5 mg/day (for 7 days), and
tofisopam 100 mg/day but causing less adverse events (AEs) [58–60].
The evidence on the safety of TP Abs to S100 was obtained in clinical and
nonclinical trials. In CTs, TP Abs to S100 exerted less AEs typical for other anti-
anxiety medications such as daytime sleepiness and muscle relaxation. No cases of
withdrawal symptoms, addiction to TP Abs to S100, or negative drug interactions
have been registered up-to-date. In nonclinical trials, no myorelaxant and toxic
effects were observed.
In the current review, we describe the mechanisms of action and pharmacolog-
ical effects of TP Abs to S100 demonstrated in nonclinical (preclinical) and clinical
3
Technologically Processed Highly Diluted Antibodies to S100 Protein in the Treatment…
DOI: http://dx.doi.org/10.5772/intechopen.92207
studies. Based on the data, we attempt to evaluate the future perspectives of the TP
Abs to S100 as the drug of choice for ND treatment.
2. Preclinical trials of technologically processed highly diluted
antibodies to S100 protein
2.1 Pharmacodynamics
2.1.1 Biological activity
2.1.1.1 Antistress activity of TP Abs to S100
Antistress activity of TP Abs to S100 was studied using three approaches.
2.1.1.1.1 Effect on somato-vegetative manifestations of stress
Negative emotions arising from stress caused by the anticipation of pain or other
negative expectations (in particular, on the eve of surgical operations, educational
tests, important meetings, etc.) are accompanied by anxiety and fear. Concurrently,
a cascade of somato-vegetative manifestations of stress is initiated [61].
Modeling of a conditioned emotional reflex to unescapable electric pain stimu-
lation was performed on outbred white male rats weighing 220–280 g [27]. This was
followed by monitoring of animal behavior in a stressful situation (repeated place-
ment in an experimental ‘dangerous’ camera) as well as emotional responses when
stress was intensified by an additional negative provocation (approaching an unfa-
miliar object to the animal’s head). Antistress activities of TP Abs to S100 and
diazepam (‘classical’ benzodiazepine tranquilizer, positive control) were estimated
by administering drugs one day after development of the conditioned reflex.
Rats in the control group (hereinafter, animals that received distilled water as a
placebo) when they were subsequently placed in a “dangerous” chamber responded
by freezing (45%) or actively trying to escape the chamber (35%) (Table 1A). Only
20% of rats showed calm behavior. At the same time, somato-vegetative manifes-
tations of stress were observed in animals (especially with a passive reaction):
increased frequency of breathing, urination, defecation, and squeaking. Both TP
Abs to S100 and diazepam caused a decrease in the number of rats with a passive
and active response to stress, as well as significantly (three times) increased the
number of animals with a calm orientation-exploratory activity. Somato-vegetative
manifestations of stress also dissipated in both groups.
The emotional reaction of anxiety and anxiety associated with the expectation
of pain in a “dangerous” chamber was significantly enhanced when using addi-
tional provocation—bringing an unfamiliar object to the head of the animal. This
was manifested as an increase in the number of rats with active (up to 40%) and
passive (up to 55%) behavior and a decrease in the number of animals with calm
behavior (down to 5%) (Table 1B). Respiratory symptoms, squeaking, frequency
of defecation, and urination also increased. Both drugs (TP Abs to S100 and
diazepam) reduced the severity of stress induced by expectation of pain. TP Abs to
S100 reduced both the number of animals with a spontaneous active and passive
reaction by 20%, while diazepam reduced the number of animals with active
attempts to escape the chamber (by 35%) more than the number of animals with
freezing (only by 10%). The same trend continued with additional negative
provocation, which may be the result of the sedative activity of diazepam, which
TP Abs to S100 do not have.
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2.1.1.1.2 Effect on c-Fos protein expression
It is known that immediate-early response c-fos gene expression in the hypotha-
lamic paraventricular nucleus is one of the primary biological markers of stress [62].
The effectiveness of stress-protective compounds can be assessed by their ability to
suppress c-fos expression in the brain.
The study was conducted on male Wistar rats weighing 250–280 g [63], classi-
fied as active or passive (stress-resistant or predisposed to stress, respectively) in
the open field (OF) test [64]. The OF test is widely used to study the behavior of
rats [65]: animals are placed in the center of the OF arena and the horizontal and
vertical activity, the number of entries into the center zone, as well as the number
of acts of defecation and urination (emotionality) is recorded.
Rats were administered TP Abs to S100 or imipramine (antidepressant drug that
modulates c-fos expression) and then subjected to 1-hour immobilization with
simultaneous electrocutaneous irritation. Immunohistochemical detection of c-Fos
protein in the parvocellular neurons of the paraventricular nucleus of the hypothal-
amus was performed in samples obtained 90 min after the procedure, at the peak of
the protein expression [62].
In response to stress, c-Fos protein level significantly increased (vs. intact ani-
mals) in both active and passive animals (20–25 fold), and in the latter, this increase
was more pronounced (Figure 1). TP Abs to S100 and imipramine demonstrated
equally and pronounced antistress activity in passive animals: 1.2- and 1.5-fold
decrease in the number of Fos-positive cells was observed, respectively.
Parameter [A] Stress induced by
anticipation of pain
[B] Stress induced by
anticipation of pain with
additional negative stimulation
Control Diazepam TP Abs
to S100
Control Diazepam TP Abs
to S100
Percent of animals with:
Passive behavior (freezing) 45 35 25* 55 45 15*
Active behavior with attempts to
get out of the chamber
35 5* 15* 40 5* 20*
Calm exploratory behavior 20 60* 60* 5 50* 65*
Freezing in response to
provocation
n/a n/a n/a 55 45 15*
Aggression in response to
provocation
n/a n/a n/a 40 15 10*
Hurried breathing 55 35 25* 75 40 35*
Frequency (%) of:
Squeaking 25 5* 5* 45 20* 25*
Fecal boluses 50 25* 25* 65 25* 45
Urinations 35 25 25 60 25* 25*
Note: animals were intragastrically administered distilled water (2.5 ml/kg, control),TP Abs to S100 (2.5 ml/kg), or
diazepam (1 mg/kg) at a single dose 30 minutes prior to testing. n/a, not applicable; TP Abs to S100, technologically
processed highly diluted antibodies to S100 protein.
*р < 0.05 versus corresponding control.
Bold entries were made to emphasize the results in TP Abs to S100 group.
Table 1.
TP Abs to S100 antistress activity in a model of a conditioned emotional reflex to unescapable electric pain.
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2.1.1.1.3 Effect on gastric ulcers after an immobilization stress
Another important biological marker of stress is development of ulcers in the
gastric mucosa. For example, it is known that immobilization stress is accompanied
by severe gastric ulceration [66].
The study of antistress activity of TP Abs to S100 was carried out on maleWistar
rats weighing 250–280 g, classified as active or passive in the OF test [67]. Animals
were administered TP Abs to S100 at a dose of 2.5 ml/kg for 5 consecutive days or
placebo. On the 6th day, half of the rats from each group were immobilized by
fixing their paws on a special platform for 1 h, and then the number of animals with
ulcers and total number of ulcers formed in the stomach was counted.
TP Abs to S100 decreased by 33.4% the number of animals with ulcers in the
group of passive (but not active) rats, which complements the previously obtained
results on the higher efficacy of the drug in passive, highly sensitive to stress
animals.
TP Abs to S100 also reduced the total number of ulcers in both groups by more
than 50%. Again, in control passive animals, there were 1.3 times more ulcers than
in control active ones. However, after TP Abs to S100 administration, there was no
such difference.
2.1.1.2 Anxiolytic activity of TP Abs to S100
The studies were carried out on outbred white male rats weighing 230–250 g [31]
using the most widely validated tests (the Vogel conflict test, the elevated plus maze
test, and the OF test) [65]. The activity of TP Abs to S100 was compared to
diazepam.
The conflict situation in the Vogel test was created by exposing animals to
opposing behavioral tendencies: motivation to drink and fear, when every attempt
to drink was punished by an electric shock. This lead to a significant reduction in
water consumption. Drugs with anxiolytic properties alter behavior and cause an
increase in drinking.
Figure 1.
TP Abs to S100 effect on c-Fos protein expression (stress marker) in the rat hypothalamic paraventricular
nucleus after 1-hour immobilization with simultaneous electrocutaneous irritation. Note: animals were
intragastrically administered distilled water (2.5 ml/kg, control),TP Abs to S100 (2.5 ml/kg) or imipramine
(12 mg/kg) at a single dose or for 20 days preceding stress exposure. Data are expressed as M  SD. *р < 0.05
(#р < 0.001) versus corresponding control. TP Abs to S100, technologically processed highly diluted antibodies
to S100 protein.
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To study the activity of TP Abs to S100, depending on the individual reaction to
stress, animals were grouped into highly (stress-resistant) and low active
(predisposed to stress) in the forced swim test with water wheel (Nomura test), in
which stress is modeled, and asthenia and depressive behavior are evaluated. Then,
animals were treated with TP Abs to S100 or diazepam, and the Vogel conflict test
was performed.
Anxiolytic effect of TP Abs to S100 was not inferior to that of diazepam: the
number of punished water intakes in highly active groups increased by 27.4 and
28.7%, respectively (Figure 2). Meanwhile, in low-activity animals characterized by
a predisposition to asthenia and depressive behavior [64], TP Abs to S100 efficacy
was superior to diazepam (2.8 and 2 times vs. control, respectively). The data
obtained indicate that in addition to the anxiolytic activity TP Abs to S100 have an
antiasthenia activating effect, which distinguishes them from diazepam that
induces both anxiolytic and sedative effects.
The elevated plus maze test is based on the fear of heights and open spaces:
animals are placed on the central platform of the maze and the latent period before
the first entry into the open arms, the number of full and incomplete entries and the
duration of stay in them, as well as the number of head dips below the level of the
open arms is recorded.
It was established that TP Abs to S100 and diazepam had a similar anxiolytic
effect in this test: both drugs increased the number of entries into the open arms
(1.9 and 2.3 times, respectively), the time spent in the open arms (5.4 and 7 times),
as well as the number of head dips (5 and 9 times) versus control animals (Table 2).
In the OF test, the antianxiety activity of TP Abs to S100 and diazepam was
demonstrated by the fact that rats began to go to the center of the field, which was
not observed in the control group (Table 3). However, unlike diazepam, which
reduced the horizontal activity of animals by 1.5 times, TP Abs to S100 did not
change this parameter and, therefore, did not have a sedative effect.
Figure 2.
TP Abs to S100 demonstrate anxiolytic activity in the Vogel conflict test. Note: animals were intragastrically
administered distilled water (2.5 ml/kg, control),TP Abs to S100 (2.5 ml/kg) or diazepam (2 mg/kg) at a
single dose 30 minutes prior to testing. Data are expressed as M  SD. *р < 0.05 versus corresponding control.
TP Abs to S100, technologically processed highly diluted antibodies to S100 protein.
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2.1.1.3 Antiaggressive activity of TP Abs to S100
Anxiety disorders are often accompanied by covert or overt aggression. The
antiaggressive activity of TP Abs to S100 was studied in the tests of motivated and
unmotivated aggression on outbred adult white male rats weighing 200–250 g in
comparison with diazepam [68].
In the test of unmotivated aggression caused by inescapable shock, the threshold of
aggressive response of a pair of animals placed on a grid floor was determined by
increasing the stimulating current. Animals manifested shock-elicited aggression
when they assumed upright “boxing” posture and tried to bite and strike each other
with front and hind paws.
TP Abs to S100 and diazepam after a single dose and course administration
exerted antiaggressive activity: single TP Abs to S100 administration increased the
threshold of aggressive response by 23.1%, and after a 4-day administration—by
31.3% compared with the control, while diazepam increased this threshold by 26.3
and 34.9%, respectively (Figure 3).
The test of motivated aggression is based on the study of the intensity of the
aggressive reaction elicited in a pair of rats trying to escape electric shock. Rats were
individually taught to avoid pain caused by electric irritation of the paws on a safe
bench installed in the center of the chamber. Then, they were placed in pairs in the
chamber, and their behavior was observed for 2 min. Control animals began to fight
for a safety on the bench, which had a capacity to tightly fit both animals. The
criterion for the effectiveness of substances with antiaggressive action in this test
was the duration of joint avoidance of pain exposure.
Parameter
group
Number of entries into
open arms
Number of entries into
enclosed arms
Time spent in open
arms, sec
Number of
head dips
Control 1.1  0.55 2.8  0.65 12.1  8.15 0.5  0.43
Diazepam 2.6  0.80* 1.5  0.8 85.3  38.5* 4.5  1.12*
TP Abs to
S100
2.1  0.42* 2.3  0.48 65.427.5* 2.4  0.95*
Note: animals were intragastrically administered distilled water (2.5 ml/kg, control),TP Abs to S100 (2.5 ml/kg), or diazepam
(2 mg/kg) at a single dose 30 minutes prior to testing. Data are expressed as M  SD. TP Abs to S100, technologically processed highly
diluted antibodies to S100 protein.
*р < 0.05 versus control.
Bold entries were made to emphasize the results in TP Abs to S100 group.
Table 2.
TP Abs to S100 anxiolytic activity in the elevated plus maze test.
Parameter
group
Number of entries into the arena
center
Horizontal
activity
Vertical
activity
Exploratory
activity
Control 0  0 18.2  2.4 8.2  3.3 11.1  3.1
Diazepam 1.8  0.9* 12.5  1.8* 6.2  1.4 8.7  1.5
TP Abs to S100 2.4  0.7* 15.8  2.1 5.8  2.6 8.9  1.6
Note: animals were intragastrically administered distilled water (2.5 ml/kg, control),TP Abs to S100 (2.5 ml/kg), or diazepam
(2 mg/kg) at a single dose 30 minutes prior to testing. Data are expressed as M  SD. TP Abs to S100, technologically processed
highly diluted antibodies to S100 protein.
*
р < 0.05 versus control.
Bold entries were made to emphasize the results in TP Abs to S100 group.
Table 3.
TP Abs to S100 anxiolytic activity in the open field test.
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TP Abs to S100 and diazepam had a pronounced antiaggressive effect, increas-
ing the duration of joint avoidance: with a single dose, respectively, 3.4 and 3.1
times, and with a course—3.8 and 3.3 times (Figure 3).
2.1.1.4 Other psychotropic and neurotropic activities of TP Abs to S100
Along with the above-described activities (stress-protective and anxiolytic), TP
Abs to S100 were shown to exert:
• antidepressant effect in Porsolt’s and Nomura’s forced swimming tests [30, 31, 34];
• antiamnestic and neuroprotective effects in the models of ischemic and
hemorrhagic stroke [35–39], multiple sclerosis [69], Alzheimer's disease [36],
attention deficit hyperactivity disorder [37], and in vitro glucose and oxygen
deprivation [70].
2.2 Mechanisms of action of TP Abs to S100
TP Abs to S100 belong to a novel class of drugs that are produced from various
antibodies (drug substances) using a single technological platform. This technology
allows to obtain active pharmaceutical ingredients that, while retaining antibody
specificity (targeting), exert a modulating effect on the target and its biological
activity [71–73]. As the endogenous target of TP Abs to S100 is the brain-specific
protein S100 that can influence functional activity of GABA-, serotonin-, dopa-
mine-, noradrenaline-, and glutamatergic systems and sigma1 receptors [74–78],
these CNS elements had been studied while screening TP Abs to S100 mechanisms
of action (Figure 7). For this purpose, various in vivo and in vitro approaches have
been used (including the in vitro assessment of receptor’s functional activity pro-
viding the validated protocols existed).
Figure 3.
TP Abs to S100 and diazepam effects on rat’s aggressive reaction parameters in the tests of motivated and
unmotivated aggression. Note: animals were intragastrically administered distilled water (2.5 ml/kg, control),
TP Abs to S100 (2.5 ml/kg) or diazepam (2 mg/kg) at a single dose or for 5 days (2 times per day) prior to
testing. Data are expressed as M  SD. *р < 0.05 versus corresponding control. TP Abs to S100, technologically
processed highly diluted antibodies to S100 protein.
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2.2.1 GABA-ergic system involvement in TP Abs to S100 mechanisms of action
2.2.1.1 GABA-A-ergic system
To assess the role of this system in the implementation of TP Abs to S100
anxiolytic effect, GABA-A receptors were selectively blocked, and the behavior of
animals was evaluated in the Vogel conflict test [29].
The study was performed on outbred white male rats weighing 230–250 g.
Before testing, animals were administered TP Abs to S100 or diazepam. For block-
ade of the GABA-A receptors and the chloride channel of the GABA-
benzodiazepine receptor complex, bicuculline and picrotoxin, respectively, were
administered simultaneously with the tested drugs.
With blockade of the GABA-A receptor, a 1.8-fold decrease in the anticonflict
effect of TP Abs to S100 was observed, and a 2-fold decrease with diazepam; with
blockade of the chlorine channel—1.6 and 2.4-fold decrease, respectively
(Figure 4). The data obtained indicate the involvement of the abovementioned
subunits of the GABA-benzodiazepine-chloride ionophore receptor complex in the
implementation of the anxiolytic effect of TP Abs to S100.
2.2.1.2 GABA-B-ergic system
In this experiment, GABA-B receptors were selectively stimulated or blocked
and anxiolytic or antidepressant effects of TP Abs to S100, diazepam and amitrip-
tyline were evaluated in the Vogel conflict test and the Nomura test [40].
Outbred white male rats weighing 200–250 g were pretreated with baclofen, a
selective agonist of GABA-B receptors, or phaclofen, an antagonist of GABA-B
receptors. Then, the animals were administered test drugs, and their effect was
evaluated.
In the Vogel conflict test, baclofen reduced the anxiolytic effect of TP Abs to
S100 by 2.2-fold and did not affect the effect of diazepam. Phaclofen increased the
anxiolytic effect of TP Abs to S100 by 1.4-fold (Figure 5). Moreover, as expected,
none of the ligands influenced the effect of diazepam.
Figure 4.
Influence of GABA-A-ergic agents on anxiolytic activity of TP Abs to S100 and diazepam in the Vogel conflict
test. Note: animals were intragastrically administered distilled water (2.5 ml/kg, control),TP Abs to S100 (2.5
ml/kg) or diazepam (2 mg/kg) at a single dose alone or simultaneously with GABA-A receptor antagonist
bicuculline (1 mg/kg) or GABA-benzodiazepine receptor complex chloride channel blocker picrotoxin (1 mg/
kg) 30 minutes prior to testing. Data are expressed as M  SD. * р < 0.05 versus control, # р < 0.05 versus TP
Abs to S100 or diazepam. TP Abs to S100, technologically processed highly diluted antibodies to S100 protein.
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In the forced swim test, baclofen and phaclofen reduced the antidepressant
effect of TP Abs to S100 by 1.5 and 2-fold, respectively, whereas these ligands did
not affect the effectiveness of amitriptyline.
Thus, it was shown that the GABA-B-ergic system is involved in the realization
of both the anxiolytic and antidepressant effects of TP Abs to S100.
In an in vitro study, the ability of TP Abs to S100 to influence binding of the
standard radioligands to the corresponding GABA receptors and to change the
effect of the standard GABA-B1А/B2 receptor agonist (using functional analysis—
measuring [35S]GTPγS incorporation into G-proteins) was investigated [41]. The
study was performed on the cell membranes of Chinese hamster cells (CHO) and
human embryonic kidney cells (HEK293) that expressed human recombinant
GABA-B1А/B2 receptors.
In the presence of TP Abs to S100, a 25.8% decrease in standard ligand binding
to GABA-B1А/B2 receptor was observed, as well as 30.2% inhibition of the GABA-
B1A/B2 receptor's agonist-induced response was observed.
2.2.2 Serotoninergic system involvement in TP Abs to S100 mechanisms of action
Similarly, this hypothesis was studied in experiments in vivo and in vitro.
For the in vivo experiments, ketanserin, a blocker of 5-НТ2/5-НТ1С receptors
involved in the development of both anxiety and depression, and the 5HT precur-
sor, 5-hydroxytryptophan (5HTP), were used [79].
The anxiolytic effect of TP Abs to S100 was studied using the Vogel conflict test
[30]. The antidepressant effect of the drugs was determined using the Nomura test
[30]. Outbred white male rats weighing 200–250 g were pretreated with ketanserin
or 5HTP, and before testing, they received a single dose of TP Abs to S100 or
diazepam.
Ketanserin and 5HTP reduced both anxiolytic (2 and 1.3-fold, respectively) and
antidepressant effects of TP Abs to S100 (2- and 1.6-fold, respectively) (Figure 6).
Thus, it was demonstrated that the 5HT system is involved in the realization of
both the anxiolytic and antidepressant effects of TP Abs to S100.
In an in vitro study, the ability of TP Abs to S100 to influence binding of
standard radiolabeled ligands to the corresponding 5HT receptors and the ability to
change the magnitude of the effect on binding of standard ligands to their receptors
Figure 5.
Influence of GABA-В-ergic agents on anxiolytic and antidepressant activity of TP Abs to S100, diazepam, and
amitriptyline in the Vogel conflict test and the Nomura test. Note: animals were intragastrically administered
distilled water (2.5 ml/kg, control),TP Abs to S100 (2.5 ml/kg), diazepam (2 mg/kg), or amitriptyline (10
mg/kg) at a single dose. GABA-B receptors agonist baclofen (1 mg/kg) or antagonist phaclofen (10 mg/kg) were
intraperitoneally administered 40 min prior to testing and 10 min prior to the administration of the drugs.
Data are expressed as M  SD. * р < 0.05 versus control, # р < 0.05 versus TP Abs to S100. TP Abs to S100,
technologically processed highly diluted antibodies to S100 protein.
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were tested. The latter was investigated using a functional analysis of the binding of
[35S]GTPγS, calcium mobilization assay, and dielectric spectroscopy or by measur-
ing the intracellular concentration of cAMP using HTRF (Homogenous Time
Resolved Fluorescence) technology. The experiments were performed on CHO cells
stably expressing human 5HT1A, 5HT1B, 5HT1D, 5HT1E, 5HT1F, 5HT2A, 5HT2B,
5HT2Cedited, 5HT3, 5HT4, 5HT6, or 5HT7 receptors [41].
TP Abs to S100 increased binding of the corresponding standard ligands to
5HT1A (19.0%), 5HT1F (42.0%), 5HT2B (31.9%), 5HT2Cedited (49.3%), and 5HT3
(20.7%) receptors. Moreover, the drug enhanced the effect of 5HT1A receptor
agonist by 27.8% and reduced the effect of 5HT1B receptor agonist by 27.5%.
2.2.3 Dopaminergic system involvement in TP Abs to S100 mechanisms of action
The in vitro experiment was carried out similar to the study of the effect of TP
Abs to S100 on dopamine receptors [41].
The study was performed on CHO, HEK293, and pituitary rat tumor cells (GH4)
stably expressing human D1, D2L, D2S, D3, D4.4 or D5 receptors.
TP Abs to S100 increased binding of the standard ligand to the human D3
receptor by 26.3% and reduced the effect of an agonist of this type of receptor by
32.8%.
2.2.4 Glutamatergic system involvement in TP Abs to S100 mechanisms of action
In this study that was performed in vitro using rat cerebral cortex cells, TP Abs to
S100 significantly reduced binding of the standard radiolabeled ligand to the gly-
cine site of NMDA receptors [80].
2.2.5 Sigma1 receptors involvement in TP Abs to S100 mechanisms of action
The study was carried out in vitro using MCF-7 or Jurkat cells [41].
TP Abs to S100 significantly (by 24.7–56.7%) reduced binding of the standard
radiolabeled ligand to human sigma1 receptors (Figure 7).
Figure 6.
Influence of serotoninergic agents on anxiolytic and antidepressant activity of TP Abs to S100, diazepam, and
amitriptyline in the Vogel conflict test and the Nomura test. Note: animals were intragastrically administered
distilled water (2.5 ml/kg, control),TP Abs to S100 (2.5 ml/kg), diazepam (2 mg/kg), or amitriptyline (15
mg/kg) at a single dose. 5-НТ2 receptors antagonist ketanserin (1 mg/kg) or the serotonin precursor 5-
hydroxytryptophan (5-HTP, 50 mg/kg) were intraperitoneally administered 40 min prior to testing and 10
min prior to administration of the drugs. Data are expressed as M  SD. * р < 0.05 versus control, # р < 0.05
versus TP Abs to S100. TP Abs to S100, technologically processed highly diluted antibodies to S100 protein.
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2.3 Safety investigation
2.3.1 Assessment of a possible sedative effect
The study was performed on outbred white male rats weighing 230–250 g. Prior
to testing (in OF test), animals were administered TP Abs to S100 or diazepam. The
sedative effect was evaluated by a decrease in the horizontal activity of rats [7].
TP Abs to S100 did not decrease the motor activity of animals, while diazepam
decreased this parameter by 1.5 times.
2.3.2 Assessment of a possible muscle relaxant effect
This activity was investigated in the rotarod test on outbred white male rats
weighing 230–250 g [33]. Before testing, animals were administered TP Abs to S100
or diazepam. Then, the time before falling off the rotating rod and the number of
rats that fell off were recorded.
TP Abs to S100 did not affect the coordination of movements and did not have a
muscle relaxant effect. In contrast, only 30% of rats from diazepam group were able
to keep balance.
2.3.3 Toxicological studies of TP Abs to S100
The drug safety investigation was performed in accordance with principles of
Good Laboratory Practice. It included studies of the single and repeat dose
Figure 7.
Schematic representation of TP Abs to S100 mechanisms of action. Note: TP Abs to S100 (technologically
processed highly diluted antibodies to S100 protein) molecular target—brain-specific S100 protein. This
protein is secreted mainly by astrocytes in the CNS and considered to be an important regulator of many
intracellular and extracellular processes (e.g., protein phosphorylation, activity of various enzymes, the
dynamics of cytoskeleton components, binding of transcription factors, calcium homeostasis, cell proliferation
and differentiation, generation and transmission of nerve impulses, and synaptic transmission [81]). Moreover,
S100 proteins interact with almost every neurotransmitter system (serotonin-, dopamine-, GABA-,
glutamatergic, etc.) and sigma1 receptors [74–78]. TP Abs to S100 possess their pharmacological effects via
modulating activity of brain-specific S100 protein and influencing functions of the major neurotransmitter
systems as well as sigma1 receptors. In vivo studies [29, 40] revealed 5-HT2a, GABAA, and GABAB receptor
involvement in the drug psychotropic effects. Also, the drug was shown to normalize noradrenaline level [82]. In
vitro studies [41, 42] have shown that TP Abs to S100 increase standard radioligand binding to 5-HT1F, 5-
HT2B, 5-HT2Cedited, 5-HT3, NMDA, and D3 receptors. In addition, the drug inhibits binding of specific
radioligands to GABAB1A/B2 and sigma1 receptors and exerts antagonism at GABAB1A/B2, 5-HT1B, and D3
receptors and agonism at 5-HT1A receptor. The above listed TP Abs to S100 activities at the molecular level are
involved in maintaining both emotional and physiological homeostasis, and thereby, the drug exerts its stress-
protective, anxiolytic, antiamnestic, antidepressant, neuroprotective, and other activities.
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toxicities, genotoxicity, reproductive and developmental toxicity, immunotoxicity,
and local tolerance.
TP Abs to S100 exerted no toxic effects even at a dose significantly exceeding
the human recommended daily dose. The drug was shown to be well tolerated and
thereby considered to be a low-hazard substance.
3. Clinical efficacy and safety of TP Abs to S100 protein in the treatment
of NDs
3.1 Treatment of AD, AjD, SD, and neurasthenia
To date, 453 patients with AD, AjD, and neurasthenia took part in double-blind
randomized controlled CTs (n = 2), and open-label comparative randomized CTs (n
= 4) conducted in the Russian Federation and Kazakhstan according to Interna-
tional Conference on Harmonisation Good Clinical Practice and Declaration of
Helsinki [55, 57–60, 83]. Two studies were registered and approved by the regula-
tory agency (Ministry of Health of the Russian Federation) [55, 57].
3.1.1 Placebo-controlled studies
3.1.1.1 CT in patients with AD and neurological diseases
A double-blind placebo-controlled CT of TP Abs to S100 in the treatment of AD in
patients with neurological diseases [Parkinson’s disease (PD) (G.20) and chronic
cerebrovascular diseases (CCD)—cerebral atherosclerosis (I67.2), hypertensive
encephalopathy (I67.4), unspecified sequelae of cerebral infarction (I69.3)] was
conducted in 2010 ([55], unpublished data). Sixty-two patients of both sexes aged
18–75 years were enrolled and randomized in two groups to receive TP Abs to S100 (n
= 32) 10 tablets/day or placebo 10 tablets/day. Data from all 62 patients were included
in the analysis, so that intention-to-treat and per-protocol sets were equal. The use of
any antidepressants, antipsychotics, or antianxiety medications was prohibited in CT.
The therapy of concurrent somatic and neurological diseases was permitted.
The study duration was 4 weeks with a 4-week follow-up period. Inclusion
criteria were: manifested AD, the Hospital Anxiety and Depression Scale-Anxiety
(HADS-A) score ≥ 11, signed informed consent form (ICF). The percentage of
patients with a ≥50% decrease in the severity of anxiety according to the Hamilton
Anxiety Rating Scale (HAM-A) after 4 weeks of treatment and 4-week follow-up
was set as a primary efficacy endpoint. Other efficacy endpoints were: mean
decrease in HAM-A, HADS-A, and State-Trait Anxiety Inventory (STAI) scores
after 4 weeks of treatment and 4-week follow-up. Safety was assessed based on the
results of laboratory tests (blood and urine analysis) and adverse events reports.
Mann-Whitney U test, Wilcoxon signed-rank test, Student t-test, and Fisher's exact
test were used for analysis.
The mean age of patients enrolled was 59.5  2.0 years in the TP Abs to S100
group and 60.0  1.9 years in the placebo group. The mean duration of neurological
disease was 6.13 1.2 years in the TP Abs to S100 group and 6.55 0.89 years in the
placebo group. No differences in demographic and clinical characteristics of
patients were found (Table 4).
The percentage of patients with a ≥50% decrease in HAM-A total score was
41.3% in the TP Abs to S100 group and 6.7% in the placebo group (p < 0.05
compared to placebo) after 4 weeks of therapy (Table 4). After 4 weeks of therapy,
the total HAM-A score significantly decreased in the TP Abs to S100 group
[a 1.8-fold decrease (45.63  2.61%) from baseline in the TP Abs to S100 group
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versus a 1.1-fold (or 13.09  3.3%) decrease in the placebo group; Student’s t-test
р < 0.05]. The result of therapy persisted during the follow-up period in the TP Abs
to S100 group. The anxiety level additionally decreased by 3% (48.19 2.1% from
baseline in total) by the end of the follow-up period (p < 0.05 compared to
placebo). The percentage of patients with a ≥50% decrease in HAM-A total score
additionally increased by 3.3% after 4 weeks of follow-up (p < 0.05 compared to
placebo) (Figure 8).
A significant decrease in the severity of anxiety was shown in patients receiving
TP Abs to S100 according to HADS-A after 4 weeks of therapy and 4 weeks of
follow-up (p < 0.05 compared to the placebo group). There was a 1.4-fold decrease
TP Abs to S100 Placebo
Total
(n = 32)
Patients
with PD
(n = 16)
Patients
with CCD
(n = 16)
Total
(n = 30)
Patients
with PD
(n = 15)
Patients
with CCD
(n = 15)
Demographic and clinical characteristics
Age, years 59.5  2.0 61.4  3.0 57.9  2.5 60.0  1.9 61.1  2.9 58.9  2.6
Duration of
neurological
disease, years
6.13  1.22 6.13  1.15 5.94  2.03 6.55  0.89 8.0  1.48 5.29  2.56
Baseline data
HADS-A,
score
14.75  0.46 15  0.68 14.24  0.63 15.7  0.41 16.93  0.34 14.47 
0.59
STAI, trait
anxiety, score
62.28  0.97 62.69  1.76 60.82  0.88 59.5  1.25 61.53  1.82 57.47 
1.61
STAI, state
anxiety, score
60.09  1.05 59.31  1.71 59.82  1.24 60.8  1.07 63  1.06 58.6  1.7
HAM-A, score 27.28  0.66 26.38  0.82 28.19  1.01 26.37  0.6 27.13  0.65 25.6  0.9
After 4 weeks of treatment
HADS-A,
score
7.74  0.53 8.8  0.97 6.75  0.39 12.93  0.8 16.0  0.53 9.87  1.0
STAI, trait
anxiety, score
50.58  1.25 53.2  2.27 48.13  0.82 55.93  1.55 61.07  1.55 50.8  1.95
STAI, state
anxiety, score
43.48  1.06 46.4  1.57 40.75  1.07 54.0  1.58 58.6  1.59 49.4  2.19
HAM-A, score 14.74  0.74 16.4  1.21 13.19  0.7 22.83  1.05 26.07  1.05 19.6  1.41
After 4 weeks of follow-up
HADS-A,
score
7.61  0.49 8.8  0.74 6.5  0.52 13.1  0.69 15.6  0.36 10.6  0.97
STAI, trait
anxiety, score
49.45  1.04 51.0  1.91 48.0  0.84 56.47  1.33 60.6  1.43 52.33 
1.69
STAI, state
anxiety, score
43.65  0.85 46.67  1.13 40.81  0.78 56.67  1.27 60.47  1.19 60.47 
1.19
52.87  1.8
HAM-A, score 14.13  0.68 15  1.01 13.31  0.9 24.03  0.89 26.78  0.64 21.2  1.31
Note: Data are expressed as M  SD. HAM-A, Hamilton Anxiety Rating scale; HADS-A, Hospital Anxiety and
Depression Scale-Anxiety; STAI, State-Trait Anxiety Inventory; CCD, chronic cerebrovascular disease; PD,
Parkinson’s disease; TP Abs to S100, technologically processed highly diluted antibodies to S100 protein.
Table 4.
Demographic and clinical characteristics, baseline, and post-treatment data on patients in double-blind
placebo controlled CT of TP Abs to S100.
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(60.09  1.05 vs. 43.65  0.85) in state anxiety according to STAI in the TP Abs to
S100 group after 4 weeks of therapy and result of therapy persisted during the
follow-up period. The efficacy rate in reduction of the anxiety was higher in CCD
patients than in PD patients according to STAI.
Data from 62 patients were included in the safety analysis. There were two AEs
(pyrosis and burping) in one patient received TP Abs to S100 and one AE (pyrosis)
in one patient in the placebo group. There was no significant difference in the
frequency of AEs between groups. Neither TP Abs to S100 nor placebo influenced
results of blood or urine tests in patients. All AEs were of medium severity and had
no definite relationship with the study drug. No serious AEs were registered.
TP Abs to S100 were shown to be an effective drug for the treatment of AD in
adult patients with concurrent neurological diseases.
3.1.1.2 Clinical trials in patients with SD
An international multicenter double-blind randomized placebo-controlled study
in 390 patients of both sexes aged 18–45 years with SD (mostly), AjD, or neurasthenia
and ≥11 HADS-A points was conducted in 2017–2019 in the Russian Federation and
Kazakhstan [57]. There were four treatment groups receiving TP Abs to S100 or
placebo in two dosage regimens: 4 or 8 tablets/day. Preliminary (yet unpublished)
data on primary efficacy endpoint showed the decrease in the mean HAM-A score by
11.25 points in TP Abs to S100 group (4 tablets/day) and by 11.91 points in TP Abs to
S100 8 tablets/day groups observed after 12 weeks of treatment (vs. 9.71 points in
merged placebo group; ANCOVA: pTP Abs to S100 4 tablets per day/placebo =
0.0055, pTP Abs to S100 8 tablets per day /placebo < 0.0001). A detailed analysis of
the results is currently being prepared for a publication. Complete information on the
study design is available at clinicaltrials.gov NCT 03036293 [57].
3.1.2 Comparison of the TP Abs to S100 efficacy and safety with benzodiazepines
To evaluate the advantages and limitations of novel medication, especially in the
treatment of mental disorders, it is necessary to compare its efficacy and safety not
only with placebo but also with the “golden standard” treatment [84].
Figure 8.
Dynamics of the severity of anxiety in TP Abs to S100 and placebo groups. *р < 0.05 versus placebo (Student’s
t-test). HAM-A, Hamilton Anxiety Rating scale; TP Abs to S100, technologically processed highly diluted
antibodies to S100 protein.
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Benzodiazepines are usually chosen as such a standard in CTs in patients with NDs
and, in particular, ADs. Therefore, four CTs with the use of bromdihydrochlorphe-
nylbenzodiazepine, diazepam, clonazepam, and tofisopam as the control therapy
were conducted [58–60].
3.1.2.1 Open-label comparative randomized CT of TP Abs to S100 and
bromdihydrochlorphenylbenzodiazepine
Outpatients aged 18–65 years (n = 59) with a diagnosis of GAD (F41.1), AjD
(F43.2), or neurasthenia (F48.0) who signed ICF participated in this open-label
randomized CT [58]. One group of patients (n = 32) received TP Abs to S100 4
tablets/day, and the other (n = 27) was administered bromdihydrochlorphenylben-
zodiazepine 1.5 mg/day for 28 days. Exclusion criteria were other mental diseases,
severe somatic diseases, pregnancy, or lactation period. Any medications that could
influence the emotional state of participants were prohibited for use for 1 week
prior to the initiation of CT and during the study.
Efficacy was evaluated based on the results of the HAM-A test and Clinical
Global Impression-Improvement scale (CGI-I) after 7, 14, and 28 days of treatment.
The frequency of AEs and any deviations from the reference ranges in blood and
urine tests was used for safety assessment. The Kruskal-Wallis test, ANOVA, and
Mann-Whitney U-test were used for statistical analysis.
The mean age of patients was 34.8  3.6 years in TP Abs to S100 and 36.3  4.6
years in bromdihydrochlorphenylbenzodiazepine group. The mean duration of dis-
ease was 0.8  0.6 years and 0.9  0.5 years in TP Abs to S100 and bromdihydro-
chlorphenylbenzodiazepine groups, respectively (Table 5). No significant
differences between groups in any demographic and clinical characteristics were
found.
After 7 days of treatment, the severity of anxiety was reduced by 41% (from 18.2
 3.91 to 10.73  5.02) in the TP Abs to S100 group and by 56.2% (from 21.24 
3.25 to 9.29  4.24) in the comparison group according to HAM-A scale. No signif-
icant differences between groups were found after the first week of treatment (p =
0.41), and TP Abs to S100 were shown to be as effective as bromdihydrochlorphe-
nylbenzodiazepine in the short-term period. After 14 and 28 days the anxiolytic
effect in the group, receiving benzodiazepine drug was superior to that in the TP
Abs to S100 group (p < 0.05 between groups). In accordance with CGI-I results,
the level of improvement was found to be similar in both groups (p = 0.004) on the
7th and 14th days, but later, bromdihydrochlorphenylbenzodiazepine led to a sig-
nificant decrease in the severity of illness after 28 days of treatment (p > 0.05
between groups).
The frequency of AEs was higher in the benzodiazepine group. There were
several cases of severe daytime sleepiness, disturbance of accommodation, and
muscle weakness in patients that received bromdihydrochlorphenylbenzo-
diazepine. Some patients in the study group reported mild sleepiness. No severe
AEs were registered in the TP Abs to S100 group. Neither TP Abs to S100 nor
benzodiazepine administration affected results of blood or urine tests in patients.
Thus, TP Abs to S100 were as effective as the control medication only in the
short-term period according to HAM-A but caused no severe AEs in patients with
GAD, AjD, and neurasthenia comparing to benzodiazepine.
3.1.2.2 Open-label comparative randomized CT of TP Abs to S100 and diazepam
Diazepam is the most frequent standard drug used in CTs of anxiolytic agents
[85]. This open-label randomized CT was conducted under the regulation of the
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Ministry of Health of the Russian Federation [unpublished data]. Outpatients aged
18–65 years with GAD (F41.1), AjD (F43.2), neurasthenia (F48.0) (total n = 272),
and mixed anxiety and depressive disorder (mADD) (F41.2) signed ICF and then
were randomized to receive TP Abs to S100 (n = 142) 6 tablets/day or diazepam
(n = 130) 15 mg/day for 28 days. All medications influencing the emotional state
were prohibited for use 1 week prior to CT initiation and during the study. Diagno-
sis of any other psychiatric disorder, pregnancy, lactation period, substance abuse,
and severe somatic diseases were set as the exclusion criteria. Efficacy was mea-
sured using the HAM-A scale and STAI. Safety was assessed based on the AE reports
and results of blood and urine tests.
The mean age of patients was 40.4  1.13 in TP Abs to S100 group and 39.6 
1.06 in the diazepam group. The mean duration of NDs was 31.9  4.1 and 29.2 
3.23 months in the TP Abs to S100 and diazepam groups, respectively. In the TP
Abs to S100 group, 27.5% of patients had GAD, 31.3%—neurasthenia, 24.4%—AjD,
and 17%—mADD. Among patients administered diazepam 31.6% had GAD, 37%—
neurasthenia, 17.5%—AjD, and 14.8%—mADD. Mean HAM-A score was 27.1  0.5
in the TP Abs to S100 group and 28.1  0.46 in the diazepam group (p = 0.3). No
differences in baseline characteristics were observed.
The total HAM-A score decreased to 22.0  0.5 in TP Abs to S100 group at the
end of the first week of therapy (p < 0.001 compared to baseline). There was a
57.2% decrease in total HAM-A score in the TP Abs to S100 group after 28 days of
treatment (vs. 63% in the diazepam group, p = 0.02) (Figure 9).
The percentage of patients with a ≥50% decrease in HAM-A total score was
72.6% in the TP Abs to S100 group (vs. 65.8% in the diazepam group) after 28 days
of treatment. There were 12.8% of patients in TP Abs to S100 group with anxiety
remission (less than 7 HAM-A scores) (vs. 22.1% in diazepam group). There were
no significant differences between the TP Abs to S100 and diazepam groups on 7th
TP Abs to S100 Bromdihydrochlorphenylbenzodiazepine p
Demographic and clinical characteristics
Age, years 34.8  3.6 36.3  4.6 >0.05
Disease duration, years 0.8  0.6 0.9  0.5 >0.05
Baseline data
HAM-A, score 18.2  3.91 21.24  3.25 0.41
After 7 days of treatment
HAM-A, score 10.73  5.02 9.29  4.24 0.46
CGI-I, score 3.41  1.1 3.05  0.97 0.28
After 14 days of treatment
HAM-A, score 11.14  5.49 6.62  2.80 0.003
CGI-I, score 3.14  1.13 2.33  1.39 0.004
After 28 days of treatment
HAM-A, score 9.59  6.08 5.62  2.18 0.000023
CGI-I, score 2.86  1.58 2.33  1.06 0.21
Note: Data are expressed as M  SD. HAM-A, Hamilton Anxiety Rating scale; CGI-I, Clinical Global Impression-
Improvement scale; TP Abs to S100, technologically processed highly diluted antibodies to S100 protein.
Table 5.
Demographic and clinical characteristics, baseline, and post-treatment data of patients in comparative CT of
TP Abs to S100 and bromdihydrochlorphenylbenzodiazepine.
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and 28th days of treatment according to the HAM-A section “anxiety mood” (p =
0.2 and p = 0.1 between groups). Treatment with diazepam was more effective only
at the 14th day of treatment [48.0  0.62 (diazepam) vs. 50.0  0.52 (TP Abs to
S100), p = 0.02 comparing to the TP Abs to S100 group] according to STAI (state
anxiety). The influence of TP Abs to S100 and diazepam on state anxiety was equal
on the 7th and 28th days of therapy (p = 0.2 between groups). Diazepam and TP As
to S100 were of equal efficacy in reducing the trait anxiety after 14 days [49.7 
0.60 (TP Abs to S100) vs. 51.0  0.55 (diazepam); p = 0.1 between groups].
Only eight (5.6%) patients in the TP Abs to S100 group reported AEs (sleepi-
ness, dizziness, dry mouth, pyrosis, bloating, excessive sweating, decreased libido,
and tachycardia) of mild and moderate severity. In contrast, in the diazepam group,
51 (39.2%) patients had AEs (most frequent—daytime sleepiness, muscle relaxa-
tion, orthostatic hypotension) (p < 0.01).
To summarize the data, we consider TP Abs to S100 less effective than diaze-
pam, though TP Abs to S100 were well tolerated by patients with GAD, AjD,
neurasthenia, or mADD and exerted significantly less AEs in contrast to diazepam.
3.1.2.3 Open-label comparative randomized CT of TP Abs to S100 and clonazepam
In this open-label CT, 60 patients with AjD (n = 35) or SD (n = 25) and cardio-
vascular diseases (CVDs) (coronary heart disease (CHD), arterial hypertension
(AH) grades II–III, postmyocarditis cardiosclerosis, dyshormonal myocardial dys-
trophy with cardiac arrhythmias, ventricular and supraventricular extrasystoles,
atrial fibrillation, and heart defects) were randomly prescribed to receive TP Abs to
S100 6 tablets/day (n = 30) or clonazepam 0.5–1 mg/day (n = 20) as an anxiolytic
treatment in addition to standard therapy of CVD for 28 days after signing an ICF
[59]. The control group (n = 10) was not administered any antianxiety medication.
No drugs influencing the mental status of participants were allowed 1 week prior to
CT and after the onset of CT. The reduction of HAM-A score was set as an efficacy
endpoint. Safety was assessed based on the number of reported AEs, changes in
electrocardiogram (in TP Abs to S100 group), and results of blood and urine tests.
At the baseline mean, HAM-A score was 20.75  8.3 in the TP Abs to S100
group, 22.3  8.1 in the clonazepam group, and 14.7  5.6 in control. After 28 days
Figure 9.
Dynamics of the severity of anxiety in the TP Abs to S100 and diazepam groups. * р < 0.05 versus baseline.
HAM-A, Hamilton Anxiety Rating Scale; TP Abs to S100, technologically processed highly diluted antibodies
to S100 protein.
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of treatment, the mean HAM-A score was reduced by 30.1% in patients that
received TP Abs to S100 (to 14.5  5.6; p < 0.01 vs. baseline), by 30.04% in the
clonazepam group (to 15.6  6.2; p < 0.01 vs. baseline) and 24.5% in the control
group (to 11.1  4.1; p > 0.05 vs. baseline). Patients in the TP Abs to S100 group
reported no AEs and no changes were found on electrocardiogram or blood and
urine tests. On the contrary, the extrasystoles in two participants with dyshormonal
myocardial dystrophy that received TP Abs to S100 became less frequent (from
3122 to 2040) after 14 days of treatment. Patients in the clonazepam group (n = 5)
noted a slowdown in mental and motor reactions, a feeling of tiredness, and day-
time sleepiness.
Thus, TP Abs to S100 appeared to be slightly less effective than clonazepam but
at the same time exerted less AEs that are important for patients with not only the
AjD alone but also for those with CVD.
3.1.2.4 Open-label comparative randomized CT of TP Abs to S100 and tofisopam
Patients (n = 51) with GAD or mADD and CVD (CHD or AH grades II–III)
signed ICF and then were randomized into two groups. The first group (n = 31)
received TP Abs to S100 4 tablets/day, the second (n = 20)—tofisopam 100 mg/day
for 4 weeks in addition to standard CVD therapy [60]. After 4 weeks of
treatment, patients were followed up for the next 4 weeks. Patients that previously
received antianxiety or antidepressant medications, diagnosed with other mental
diseases, having a history of substance abuse or lactose intolerance were not
included in CT. The changes in HAM-A score after 2 and 4 weeks of treatment and
after 4-week follow-up were set as efficacy endpoints. Safety was evaluated by
analysis of AEs.
The mean age of patients in the TP Abs to S100 group was 49.3  7.0 years, and
the mean duration of CVD was 8.2  4.5 years. In the tofisopam group, the mean
age was 54  5.2, and the duration of CVD was 7.6  2.9 years. No differences in
baseline characteristics were registered. During the treatment, anxiety was reduced
by 63% after 1 week, by 73.1% after 2 weeks, and by 78.5% after 4 weeks in the TP
Abs to S100 group according to HAM-A. There was a decrease in HAM-A scores by
62.5% after 1 week, by 75% after 2 weeks, and by 78.5% after 4 weeks in the
tofisopam group. A positive effect of TP Abs to S100 on anxiety state was
maintained for 4 weeks during follow-up, while there was a tendency for an
increase in HAM-A score in the tofisopam group. The addition of TP Abs to S100 to
standard CVD therapy helped to decrease the mean systolic blood pressure (SBP)
by 25% (from 161.5  18.5 mmHg to 122  5.0 mmHg) after 4 weeks of treatment,
whereas only 15.9% decrease in mean SBP was shown in the tofisopam group. No
serious AEs were registered in both groups. In the TP Abs to S100 and tofisopam
groups, 3.2 and 10% of patients, respectively, discontinued the treatment for
personal reasons.
Thus, TP Abs to S100 were shown to be as effective as tofisopam. The compli-
ance in the TP Abs to S100 group was slightly higher than that in the tofisopam
group. The addition of TP Abs to S100 to standard CVD treatment led to a more
prominent decrease in the mean SBP than the addition of tofisopam. TP Abs to S100
achieved more prolonged action on anxiety state than tofisopam.
3.2 Treatment of anxiety, accompanying somatic diseases
The use of anxiolytic treatment in the patients with chronic somatic diseases is
challenging [86]. Many side effects of benzodiazepines such as drowsiness, sleepi-
ness, cognitive impairment, dizziness, and addiction can be crucial for these
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patients [87]. Polypharmacy is also an unwanted phenomenon. The negative inter-
action of antianxiety medications with standard therapy of somatic diseases is
frequently observed [88]. For instance, the use of SSRI in combination with non-
steroidal anti-inflammatory drugs increases the risk of gastrointestinal tract bleed-
ing [89]. Some authors described the association between high risk of myocardial
infarction and the use of benzodiazepines and antidepressants [90]. So, the search
for a possible role of TP Abs to S100 in treatment of patients with the somatic
disease is relevant.
3.2.1 Cardiovascular diseases
Around 40% of patients with CVD experience anxiety that can have a negative
impact on the risk of adverse cardiovascular events [91, 92]. Thus, it is important to
reduce anxiety symptoms in CVD patients.
Two CTs that compared TP Abs to S100 with clonazepam and tofisopam in
patients with CVD were described above [59, 60]. The results showed equal efficacy
of TP Abs to S100 and tofisopam in CVD patients.
In another open-label randomized comparative CT by Nikol'skaya et al., TP Abs
to S100 were used in combination with the standard treatment of patients with AH
grades II–III and anxiety (n = 60, 23 women, 37 men; mean age—61.4  6.9, mean
AH duration—10.6 4.1 years) [93]. All patients received diuretics, β blockers, and
angiotensin-converting-enzyme inhibitors (ACE inhibitors). Randomly chosen
participants (n = 30) were additionally prescribed TP Abs to S100 6 tablets/day for
4 weeks. At the baseline, there were 40% of patients with severe anxiety and 60%
with the anxiety of moderate severity in the TP Abs to S100 group according to the
Taylor Manifest Anxiety Scale (TMAS) modified by Nemchinov. Sixty percent of
patients with severe anxiety and 56.6% with the anxiety of moderate severity made
up the control group were receiving no antianxiety therapy.
The 1.3-fold reduction of severity of anxiety (from 23.76  2.81 to 18.83  2.75
TMAS points) after 2 weeks of therapy was shown in the TP Abs to S100 group
(p < 0.0001 vs. baseline and the control group). There was a 24.28% decrease in
SBP from 181.7  10.8 to 140.0  8.3 (p < 0.0001 vs. baseline and control) after 4
weeks of therapy in the TP Abs to S100 group. There was a 17.7% decrease in
diastolic blood pressure from 102.3  4.3 to 85.0  5.7 in the study drug group
after 4 weeks of therapy (p < 0.0001 vs. baseline and the control group). No
negative interactions with standard therapy were registered for TP Abs to S100.
Matyushin et al. demonstrated the efficacy and safety of TP Abs to S100 in an
open-label randomized comparative CT in patients (n = 60) with anxiety measured
with HAM-A and CHD, AH grades II–III, angina pectoris I–III functional classes by
Canadian Cardiovascular Society Classification, heart rhythm disturbances (extra-
systole, paroxysmal supraventricular tachyarrhythmias) receiving standard CVD
therapy (β blockers, amiodarone, sotalol, lappaconitine hydrobromide, diethylami-
nopropionylethoxycarbonylaminophenothiazine, etc.) [94]. The study drug group
(n = 30) received TP Abs to S100 6 tablets/day, and the control group (n = 30) was
administered only CVD treatment for 8 weeks. The mean age of patients in TP Abs
to S100 and control groups was 64.4  8.6 and 63.1  8.5, respectively.
The addition of TP Abs to S100 to the standard therapy in patients with angina
pectoris I–III functional classes helped to decrease the severity of anxiety (50.4%
decrease vs. 32.3% decrease in the TP Abs to S100 group vs. the control group;
p < 0.05) and caused cardiac rhythm normalization [80% patients with more
than 75% decrease in the frequency of daily episodes of rhythm disturbances in
the study group (p < 0.05 vs. control)]. There were 60% of patients with a
decrease in angina pectoris functional class in the study drug group (vs. 33.3% in
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control; p < 0.05 between groups). No AEs and negative drug interactions were
registered.
An open-label placebo-controlled study in 85 patients with acute coronary syn-
drome and anxiety (diagnosed with HADS-A) showed significant improvement in
the quality of life assessed with the Short Form-36 in the TP Abs to S100 group after
6 month of therapy [95]. The 1.7-fold decrease in HADS-A score (from 12.1 [9;17] to
7.1 [6;8]) was observed in patients receiving TP Abs to S100 in combination with
standard therapy after 6 months (p = 0.00008 vs. baseline). No reduction of anxiety
according to HADS-A was found in the placebo group after 6 months (p = 0.07 vs.
baseline). No negative interaction with standard therapy (acetylsalicylic acid,
clopidogrel, enoxaparin, statins, ACE inhibitors, β blockers, nitrates, calcium ago-
nists) was registered.
Thus, TP Abs to S100 is an effective anxiolytic medication that helps to reduce
the severity of anxiety as well as to avoid drug interaction, polypharmacy and
increase the quality of life. According to some CTs mentioned above, TP Abs to
S100 increase the efficacy of standard treatment in patients with AH, angina
pectoris, and some heart rhythm disturbances due to their antianxiety action. Due
to reduction in severity of anxiety, the improvement of compliance in CVD patients
is possible, though this consideration requires further investigation.
3.2.2 Gastrointestinal diseases
Anxiety is common in 20% of patients with gastrointestinal (GI) problems [96]
and in 27% of patients with gastritis in particular [97]. Some publications revealed an
association between mood disorders and the risk of carcinogenesis in patients with GI
diseases [98, 99]. The necessity for antianxiety therapy in these patients is justified.
An open-label comparative study by Tsukanov et al. in patients with anxiety
(diagnosed with HAM-A) complicating ulcerative gastritis associated with
Helicobacter pylori and duodenal ulcers was conducted [100]. One hundred and two
participants received standard helicobacter eradication therapy (clarithromycin,
amoxicillin, omeprazole, algeldrate—magnesium hydroxide combination drug), and
49 of them were prescribed TP Abs to S100 6 tablets/day for 20 days. Mean age of
participants was 41.8 2.4 in the TP Abs to S100 group (n = 49) and 42.3 2.8 in the
control group (n = 53). The dynamics of HAM-A scale scores was evaluated.
Anxiety was significantly reduced in the TP Abs to S100 group after 20 days of
treatment. The mean HAM-A score decreased by 55.2% from 23.43  1.8 to 10.5 
0.98 (vs. 28% in the control group; p < 0.001 vs. baseline; p < 0.001 vs. control
group). No serious AEs were registered in both groups.
According to another open-label noncomparative CT by Karpin et al. in patients
with chronic gastritis and duodenal ulcers, the addition of TP Abs to S100 to
standard treatment leads to a prominent reduction in GI symptoms (pain, intestinal
dyspepsia, appetite changes) (p = 0.003 vs. baseline for pain and dyspepsia, p =
0.045 for appetite changes) [101].
So, the treatment of patients with GI diseases with TP Abs to S100 helps to
reduce anxiety and indirectly decrease the severity of somatic symptoms via its
anxiolytic action.
4. Conclusions
In this review, the data obtained from experimental and clinical studies of TP
Abs to S100 efficacy, safety, and mechanisms of action are summarized.
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In nonclinical trials, TP Abs to S100 were shown to exert stress-protective,
anxiolytic, antidepressant, antiamnestic, and neuroprotective activities. All these
effects were manifested at the same level as the activity of comparator drugs. At the
same time, toxicological studies have shown a high safety level of TP Abs to S100:
there was no any toxic activity of drug reviled even when it was administered to
laboratory animals at the maximal dose for 6 consecutive months (every day).
The mechanisms of action studies confirmed the hypothesis that TP Abs to S100
biological effects are realized via recruiting of GABA-, serotonin-, dopamine-, nor-
adrenaline-, and glutamatergic systems, as well as via sigma1 receptors.
Clinical efficacy and safety of TP Abs to S100 were demonstrated in multicenter
double-blind randomized placebo-controlled trials and in open-label randomized
comparative trials. In all conducted placebo-comparative studies or studies with
nonmedicated control group, the main symptom of most NDs—the anxiety—was
significantly reduced in TP Abs to S100 action. It should be stressed that in these
CTs, the equal efficacy of TP Abs to S100, tofisopam, and bromdihydrochlorphe-
nylbenzodiazepine (in the short-term use) with a notably higher tolerance level was
demonstrated. Meanwhile, TP Abs to S100 increased the efficacy of standard treat-
ment of somatic diseases (due to its anxiolytic activity), and there was a lower
number of AEs and lack of drug interactions observed in the TP Abs to S100 group.
Thus, the discussed drug—TP Abs to S100—has been extensively studied and
demonstrated favorable efficacy and safety profile. The presented evidence justifies
TP Abs to S100 to be a promising treatment option for patients with NDs.
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